Latest Diagnostics News

Pacific Edge reports steady demand for its Cxbladder cancer diagnostic tests despite losing Medicare coverage and transitioning US customers to a new test. The company is advancing clinical evidence and a $21 million capital raise to support growth and regain coverage.

Echo IQ has secured a pivotal reseller agreement with US-based SARC MedIQ, unlocking access to over 300 healthcare facilities and accelerating adoption of its AI-driven EchoSolv AS technology across the American cardiology landscape.

Imagion Biosystems has received encouraging feedback from the FDA on its planned Phase 2 HER2 breast cancer clinical trial, paving the way for its Investigational New Drug application submission later this year.

Artrya Limited has secured a five-year, US$0.6 million contract with Tanner Health, marking its inaugural commercial revenue in the U.S. market for its AI-powered Salix Coronary Anatomy platform.

Archer Materials has successfully demonstrated its tunnel magnetoresistance (TMR) sensors operating at cryogenic temperatures, marking a key advance for quantum computing and advanced sensing applications.

Telix Pharmaceuticals has achieved a key milestone with its next-generation prostate cancer imaging agent, Gozellix, receiving a permanent HCPCS code from U.S. Medicare. This paves the way for broader reimbursement and market adoption starting October 2025.

BlinkLab has expanded its pivotal FDA autism diagnostic trial by adding the University of Nebraska Medical Center as a second U.S. clinical site, advancing toward broader validation and regulatory clearance.

dorsaVi has begun critical testing of its innovative RRAM-powered sensor systems in Singapore, targeting biomedical applications like EMG and ECG to enhance wearable device performance and energy efficiency.

BCAL Diagnostics has secured a strategic partnership with Cancer Care Associates to fast-track the clinical adoption and revenue generation of its innovative BREASTEST plus™ breast cancer blood test starting FY2026.

Proteomics International has secured a dedicated US reimbursement code for its next-generation PromarkerD test, a key step towards broader adoption in diabetic kidney disease diagnostics.

Artrya Limited announces a strategic leadership reshuffle with co-founder John Konstantopoulos stepping into the CEO role as the company prepares for its U.S. commercial launch of the Salix® AI-powered platform.

Proteomics International, alongside key partners, is investing $6 million to expand the WA Proteomics Facility, aiming to establish a nationally accredited platform for industrial-scale protein biomarker analysis in medicine and agriculture.